The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma

被引:203
作者
Kim, Tae Yong
Kim, Won Bae
Rhee, Yoon Soo
Song, Ja Young
Kim, Jung Min
Gong, Gyungyub
Lee, Seungkoo
Kim, Sang Yoon
Kim, Seong Chul
Hong, Suck Joon
Shong, Young Kee
机构
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Internal Med, Seoul 138736, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Otolaryngol, Seoul, South Korea
[4] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Surg, Seoul, South Korea
[5] Univ Ulsan, Coll Med, Asan Med Ctr, Asan Inst Life Sci, Seoul, South Korea
关键词
D O I
10.1111/j.1365-2265.2006.02605.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The activating BRAF(V600E) mutation is the most common genetic alteration reported in papillary thyroid carcinoma (PTC). While some reports suggest the BRAF(V600E) mutation is associated with factors predicting a poor prognosis and recurrence, this remains a controversial issue. Aim To determine whether the presence of the BRAF(V600E) mutation is a prognostic indicator for clinical recurrence in low-risk patients with conventional PTC. Patients and methods The study involved 203 conventional PTC patients who underwent total or near-total thyroidectomy followed by immediate I-131 ablation of the remnants. Patients with antithyroglobulin antibodies and those with extracervical metastases at presentation were excluded. DNA was extracted from paraffin-embedded tumour specimens, and the presence of the BRAF(V600E) mutation was evaluated using PCR amplification and direct sequencing. Results The BRAF(V600E) mutation was found to be present in 149 (73.4%) of 203 patients. The BRAF(V600E) mutation was correlated with male gender (P = 0.006) and with tumour size (P = 0.005). While there appeared to be an association between the BRAF(V600E) mutation and extrathyroid extension, this did not reach statistical significance (P = 0.062). During follow-up of the 203 patients (median 7.3 years; range 0.7-10.0 years), 36 (18%) patients experienced recurrence. While univariate analysis showed the BRAF(V600E) mutation was associated with tumour recurrence (21% with mutation vs 7% without mutation; P = 0.037), this association was not shown following multivariate analyses adjusting for the clinicopathological prognostic factors of age, gender, tumour size, extrathyroid extension, multifocality and lymph node metastasis. Conclusions Although the BRAF(V600E) mutation was found to be associated with a higher clinical recurrence of disease in low-risk conventional PTC patients, it was not an independent predictor.
引用
收藏
页码:364 / 368
页数:5
相关论文
共 19 条
[1]  
CADY B, 1988, SURGERY, V104, P947
[2]   NATURAL-HISTORY, TREATMENT, AND COURSE OF PAPILLARY THYROID-CARCINOMA [J].
DEGROOT, LJ ;
KAPLAN, EL ;
MCCORMICK, M ;
STRAUS, FH .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 71 (02) :414-424
[3]   BRAF mutations in an Italian cohort of thyroid cancers [J].
Fugazzola, L ;
Mannavola, D ;
Cirello, V ;
Vannucchi, G ;
Muzza, M ;
Vicentini, L ;
Beck-Peccoz, P .
CLINICAL ENDOCRINOLOGY, 2004, 61 (02) :239-243
[4]  
*INT AG RES CANC, 2004, PATH GEN TUM END ORG, P57
[5]   Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population [J].
Kim, KH ;
Kang, DW ;
Kim, SH ;
Seong, IO ;
Kang, DY .
YONSEI MEDICAL JOURNAL, 2004, 45 (05) :818-821
[6]   The BRAFV600E mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma [J].
Kim, TY ;
Kim, WB ;
Song, JY ;
Rhee, YS ;
Gong, GY ;
Cho, YM ;
Kim, SY ;
Kim, SC ;
Hong, SJ ;
Shong, YK .
CLINICAL ENDOCRINOLOGY, 2005, 63 (05) :588-593
[7]   Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma [J].
Kim, TY ;
Kim, WB ;
Kim, ES ;
Ryu, JS ;
Yeo, JS ;
Kim, SC ;
Hong, SJ ;
Shong, YK .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (03) :1440-1445
[8]   No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan [J].
Liu, RT ;
Chen, YJ ;
Chou, FF ;
Li, CL ;
Wu, WL ;
Tsai, PC ;
Huang, CC ;
Cheng, JT .
CLINICAL ENDOCRINOLOGY, 2005, 63 (04) :461-466
[9]   Current approaches to primary therapy for papillary and follicular thyroid cancer [J].
Mazzaferri, EL ;
Kloos, RT .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (04) :1447-1463
[10]   Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers [J].
Namba, H ;
Nakashima, M ;
Hayashi, T ;
Hayashida, N ;
Maeda, S ;
Rogounovitch, TI ;
Ohtsuru, A ;
Saenko, VA ;
Kanematsu, T ;
Yamashita, S .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (09) :4393-4397